Adjunctive Pharmacotherapy for Opioid Addictions

  • Julia Hodgson
  • Kevin Moore
  • Trisha Acri
  • Glenn Jordan Treisman


Psychopharmacological interventions are incredibly successful in conjunction with rehabilitative treatment for opiate addiction. However, a comprehensive approach to addictions is necessary, and while pharmacotherapy plays an important role, it is insufficient on its own. A multidisciplinary team is an important part of treatment in order to address the behavioral and psychological elements we have described in this book. The team can implement treatment effectively and hold patients accountable in their recovery. Furthermore, our patients often have psychiatric and medical comorbidity that contributes to their addiction that must be addressed for success, including health concerns such as chronic diseases like hepatitis C, HIV, and chronic pain.


Medication-assisted treatment Buprenorphine Naloxone Naltrexone Urine drug screens Pharmacotherapy Addiction treatment 


  1. 1.
    Sontag D. The double-edged drug: addiction treatment with a dark side. November 16, 2013; The New York Times. Retrieved 1/31/2019 from
  2. 2.
    Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction, DHHS publication no. SMS 07-3939. Rockville: Substance Abuse and Mental Health Services Administration; 2010.Google Scholar
  3. 3.
    Mendelson J, Flower K, Pletcher MJ, Galloway GP. Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine. Exp Clin Psychopharmacol. 2008;16(5):435–41.CrossRefGoogle Scholar
  4. 4.
    Substance Abuse and Mental Health Services Administration (SAMHSA). Medications for opioid use disorder, Treatment Improvement Protocol (TIP) Series 63, Full Document. HHS Publication No. (SMA) 18- 5063FULLDOC. Rockville: Substance Abuse and Mental Health Services Administration; 2018.Google Scholar
  5. 5.
    U.S. Food & Drug Administration. Approved Risk Evaluation and Mitigation Strategies (REMS): Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) REMS Programs. 2018. Accessed November 2018 from
  6. 6.
    National Institute on Drug Abuse. Overdose death rates. 2018. Access November 2018 from
  7. 7.
    Substance Abuse and Mental Health Services Administration. SAMHSA opioid overdose prevention toolkit: safety advise for patients, HHS publication no. SMA 13-4742. Rockville: Substance Abuse and Mental Health Services Administration; 2013.Google Scholar
  8. 8.
    Quinn R. Heroin deaths in Delco at record high; fed study ranks county fourth in state for fatal overdoses. Delaware County Daily Times. 2015. Retrieved from
  9. 9.
    Whelan, J. Update on county response to opioid overdoses. 2015. Speech presented in PA, Sharon Hill.Google Scholar
  10. 10.
    White WL, Scott CK, Dennis ML, Boyle MG. It’s time to stop kicking people out of addiction treatment. Counselor. 2005;6(2):12–25. Retrieved from Scholar
  11. 11.
    Morbidity and Mortality Weekly Report (MMWR). 2016, March 18. Accessed November 2018 from
  12. 12.
    Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for U.S. adults: National Health Interview Survey, 2012. National Center for Health Statistics. Vital Health Stat 10. 2014;260:1–161. Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Julia Hodgson
    • 1
  • Kevin Moore
    • 2
  • Trisha Acri
    • 2
  • Glenn Jordan Treisman
    • 3
  1. 1.Sharon HillUSA
  2. 2.PhiladelphiaUSA
  3. 3.BaltimoreUSA

Personalised recommendations